» Articles » PMID: 25944412

How I Manage Cerebral Vasculopathy in Children with Sickle Cell Disease

Overview
Journal Br J Haematol
Specialty Hematology
Date 2015 May 7
PMID 25944412
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease induces specific brain alterations that involve both the macrocirculation and the microcirculation. The main overt neurovascular complications in children are infarctive stroke, transient ischaemic attack and cerebral haemorrhage. Silent cerebral infarction, cognitive dysfunction and recurrent headache are also common. Cerebrovascular disease selectively affects children with the HbSS or HbS-β(0) genotypes (i.e. sickle cell anaemia). The incidence of stroke peaks between 2 and 5 years of age (1·02/100 patient-years) and increases with the severity of the anaemia. Most strokes can be prevented by annual transcranial Doppler screening from 2 to 16 years of age and providing chronic blood transfusion when this investigation shows elevated blood-flow velocities. The role for hydroxycarbamide in children with abnormal transcranial Doppler findings is under investigation. After a stroke, chronic blood transfusion is very strongly recommended, unless haematopoietic stem cell transplantation can be performed. Routine magnetic resonance imaging shows that more than one-third of children have silent cerebral infarction, which is associated with cognitive impairments. Screening for silent infarcts seems legitimate, since their presence may lead to supportive treatments. The role for more aggressive interventions such as hydroxycarbamide or chronic blood transfusion is debated.

Citing Articles

Neurocognitive impairment in Ugandan children with sickle cell anemia compared to sibling controls: a cross-sectional study.

Bangirana P, Boehme A, Birabwa A, Opoka R, Munube D, Mupere E Front Stroke. 2024; 3.

PMID: 38903696 PMC: 11188974. DOI: 10.3389/fstro.2024.1372949.


Neurocognitive Impairment in Ugandan Children with Sickle Cell Anemia Compared to Sibling Controls: A cross-sectional study.

Bangirana P, Boehme A, Birabwa A, Opoka R, Munube D, Mupere E medRxiv. 2023; .

PMID: 38014206 PMC: 10680894. DOI: 10.1101/2023.11.09.23298329.


Madrid Newborn Sickle Cell Disease Cohort: clinical outcomes, stroke prevention and survival.

Garcia-Morin M, Bardon-Cancho E, Belendez C, Dulin E, Blanco-Soto P, Puertas-Lopez C Ann Hematol. 2023; 103(2):373-383.

PMID: 37980280 DOI: 10.1007/s00277-023-05539-1.


Neurofilament light chain: A potential biomarker for cerebrovascular disease in children with sickle cell anaemia.

Green N, Rosano C, Bangirana P, Opoka R, Munube D, Kasirye P Br J Haematol. 2023; 203(3):460-467.

PMID: 37581299 PMC: 10615726. DOI: 10.1111/bjh.19036.


Application of transcranial Doppler in cerebrovascular diseases.

Wan Y, Teng X, Li S, Yang Y Front Aging Neurosci. 2022; 14:1035086.

PMID: 36425321 PMC: 9679782. DOI: 10.3389/fnagi.2022.1035086.